NEOS Neos Therapeutics Inc.

NewsSee all news

1. 13 January 2020 Neos Therapeutics Initiates and Completes Dosing in a Phase 1 Trial of NT0502 for the Treatment of Chronic Sialorrhea

   DALLAS and FORT WORTH, Texas, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products,

2. 08 November 2019 Neos Therapeutics Reports Third Quarter 2019 Financial Results

   DALLAS and FORT WORTH, Texas, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery technology to develop and

3. 01 November 2019 Neos Therapeutics to Host Third Quarter 2019 Financial and Operating Results Conference Call on November 8, 2019

   DALLAS and FORT WORTH, Texas, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery technology to develop and

4. 25 September 2019 Neos Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference

   DALLAS and FORT WORTH, Texas, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery technology to develop and

5. 29 August 2019 Neos Therapeutics to Present at Two Upcoming September Conferences

   DALLAS and FORT WORTH, Texas, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery technology to develop and